Results 41 to 50 of about 1,458,916 (304)

Development of oral anticoagulants [PDF]

British Journal of Clinical Pharmacology, 2007
Warfarin has been the drug of choice for the prophylaxis and treatment of arterial and venous thrombotic disorders for over half a century [1]. It is the only oral anticoagulant currently approved for use in the US. Warfarin, a vitamin K antagonist, inhibits four vitamin K-dependent coagulation factors including prothrombin (factor II) and factors VII,
openaire   +2 more sources

Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants

, 2021
Background: Patient's adherence to oral anticoagulant therapy is essential to prevent and treat thrombotic events. Methods: To assess the patients' adherence Morisky Medication Adherence Scale 8-items was used.
Perra F., Marongiu F., Barcellona D., Cornacchini S., Farci N., Diovaldi M., Moledda V., Mameli A.   +7 more
core   +1 more source

Reversal of direct oral anticoagulants

, 2017
Mosaad Almegren Department of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia Abstract: Reversal agents for direct oral anticoagulants (DOACs), including factor X inhibitors and direct thrombin inhibitors, are a ...
Almegren M
core   +2 more sources

New oral anticoagulants [PDF]

Canadian Medical Association Journal, 2012
These medications are approved for the prevention of venous thromboembolism after hip or knee replacement and the prevention of stroke in patients with nonvalvular atrial fibrillation. Rivaroxaban is also approved for the treatment of deep vein thrombosis in patients without symptomatic ...
Dongmei, Sun, Alejandro, Lazo-Langner
openaire   +2 more sources

Safe chest tube placement in a patient with tension pneumothorax receiving rivaroxaban therapy for non-valvular atrial fibrillation

Monaldi Archives for Chest Disease, 2020
The number of patients treated with direct oral anticoagulants is increasing worldwide. Although bleeding complications associated with direct oral anticoagulants are lower than those associated with vitamin K antagonists, the increased number of ...
Alessandro Cipriano, Matteo Parollo, Ester Taurino, Elena Venturi, Massimo Santini   +4 more
doaj   +1 more source

Medication non‐adherence as a cause of apixaban failure in venous thromboembolism: The importance of pharmacist medication reconciliation

Clinical Case Reports, 2022
Venous thromboembolism is often treated with direct oral anticoagulants. In order for direct oral anticoagulants to be effective, patients must adhere to a specific dosing strategy.
Trisha E Jethwa, Kaitlin M Moran, Michael J Maniaci   +2 more
doaj   +1 more source

Oral Antithrombotic Medication Is Associated with Improved Visual Outcomes in Eyes with Submacular Hemorrhage from Wet Age-Related Macular Degeneration

Ophthalmology Science
Purpose: To determine differences in visual acuity (VA) outcomes in eyes of patients on antithrombotics (antiplatelet agents and anticoagulants) that develop submacular hemorrhage (SMH) compared with eyes of patients who are not on antithrombotics and ...
Hemal P. Patel, MD, Cason B. Robbins, MD, Jamie J. Karl, MD, Peter Weng, MD, PhD, Lejla Vajzovic, MD, FASRS, Sharon Fekrat, MD, FASRS   +5 more
doaj   +1 more source

Management of Patients Using Oral Anticoagulant Agent in Dental Practice

Bezmiâlem Science, 2019
An increasing number of patients in our country use oral anticoagulants for the prophylaxis and treatment of thromboembolic events. The cornerstone of these groups of agents is warfarin, a vitamin K antagonist, which has been the single alternative used ...
Özge DOĞANAY, Türker YÜCESOY, Alper ALKAN   +2 more
doaj   +1 more source

A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study)

Haematologica, 2018
The outcomes of patients developing major bleeding while on oral anticoagulants remain largely unquantified. The objectives of this study were to: (i) describe the burden of major hemorrhage associated with all available oral anticoagulants in terms of ...
Laura Green, Joachim Tan, Joan K Morris, Raza Alikhan, Nicola Curry, Tamara Everington, Rhona Maclean, Khalid Saja, Simon Stanworth, Campbell Tait, Peter MacCallum   +10 more
doaj   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source